(0.29%) 5 114.69 points
(0.30%) 38 356 points
(0.31%) 15 978 points
(-0.94%) $83.06
(5.77%) $2.03
(0.37%) $2 356.00
(0.42%) $27.65
(3.99%) $958.85
(-0.22%) $0.933
(-0.38%) $10.98
(-0.53%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States...
Stats | |
---|---|
本日の出来高 | 293.00 |
平均出来高 | 3 069.00 |
時価総額 | 738.48M |
EPS | $0 ( 2024-04-26 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.39 |
ATR14 | $0 (0.00%) |
PureTech Health plc 財務諸表
Annual | 2023 |
収益: | $3.33M |
総利益: | $-1.60M (-48.14 %) |
EPS: | $-2.38 |
FY | 2023 |
収益: | $3.33M |
総利益: | $-1.60M (-48.14 %) |
EPS: | $-2.38 |
FY | 2022 |
収益: | $2.09M |
総利益: | $2.09M (100.00 %) |
EPS: | $-1.300 |
FY | 2021 |
収益: | $9.98M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.12 |
Financial Reports:
No articles found.
PureTech Health plc
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。